NPCE NeuroPace, Inc.
As of 3:59 PM ET
- NPCE
Loading chart…
- Open
- $8.14
- Previous close
- $8.14
- Day range
- 7.84 – 8.28
- 52-week range
- 5.46 – 19.60
- Volume
- 50.5K
- Avg volume (3M)
- 262.1K
- Market cap
- $282.5M
- P/E (TTM)
- −12.45
- EPS (TTM)
- −$0.56
- Beta
- 1.93
- Dividend yield
- 0.00%
- Next earnings
- Feb 11, 2027(estimated from past report dates; not yet confirmed by the company)
- Ex-dividend
- —
- Sector
- Healthcare
About NeuroPace, Inc.
NeuroPace, Inc. is a medical device company focused on brain-responsive neuromodulation for people living with epilepsy. Its core RNS System is an implantable platform designed to detect abnormal brain activity and deliver targeted stimulation in response, helping physicians manage medically refractory focal epilepsy. The company’s product portfolio includes the RNS neurostimulator, depth and cortical strip leads, and accompanying patient monitoring and programming tools that support long-term therapy and remote clinical review. NeuroPace serves hospitals and epilepsy care centers, with its technology used in specialized neurology settings where individualized treatment is critical. The company operates in the neuromodulation and epilepsy treatment markets, where it plays a distinct role by combining continuous brain signal monitoring with responsive therapy in a single commercial system.
Next report: Thu, Feb 11, 2027(estimated from past report dates; not yet confirmed by the company)
| Quarter | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Nov 12, 2026(after close) | −$0.08 | −$0.10 | +25.0% |
| Aug 11, 2026(after close) | −$0.19 | −$0.18 | −5.3% |
| Jul 10, 2026(after close) | $1.49 | $1.56 | +4.7% |
| Jun 26, 2026(after close) | −$0.12 | $0.05 | −141.7% |
| Mar 3, 2026(after close) | −$0.15 | −$0.08 | −46.7% |
NPCE doesn’t pay a dividend.
NPCE news and filings
Loading filings…
Filings from SEC EDGAR.